22 April 2024 - What is the strength of association between surrogate markers used as primary outcomes in clinical trials to support FDA approval of drugs treating non-oncologic chronic diseases and clinical outcomes?
Findings No meta-analyses of clinical trials examining the strength of association between treatment effects measured using surrogate markers and clinical outcomes were identified for 22 (59%) of 37 surrogate markers for 32 chronic diseases, whereas at least 1 was identified for 15 (41%), although few reported high-strength evidence of treatment effect associations.